FCM
ALXN

Farallon Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Farallon Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-7,707,500
Closed -$1.42B – 331
2021
Q2 		$1.42B Buy
7,707,500
+1,932,500
+33% +$332M 5.78% 3
2021
Q1 		$883M Buy
5,775,000
+3,528,100
+157% +$546M 4.39% 2
2020
Q4 		$351M Buy
+2,246,900
New +$289M 2.11% 17

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Farallon Capital Management's ALXN Position: Q3 2021 in Review

Farallon Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 7,707,500 shares — an estimated $1.42B sold.

Farallon Capital Management first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $1.42B in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Farallon Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Farallon Capital Management sold 7,707,500 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.42B.
  • Farallon Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • Farallon Capital Management's Alexion Pharmaceuticals position peaked at $1.42B in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Farallon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.